A study performed at the University of São Paulo’s Biomedical Science Institute (ICB-USP) in Brazil shows that sofosbuvir, a drug used to treat chronic hepatitis C, is capable of eliminating chikungunya virus and yellow fever virus.
“Human cells infected by chikungunya virus were treated with sofosbuvir, and the drug eliminated the virus without damaging any cells. The drug proved to be 11 times more effective against the virus than against cells,” said Rafaela Milan Bonotto, a coauthor of the study.
The study relating to chikungunya was conducted as part of Bonotto’s PhD research with a scholarship from FAPESP and supervision by Professor Lucio Freitas-Junior.
An article on the study, signed by Bonotto, Freitas-Junior and collaborators, can be found on the open platform F1000Research. An article on the group’s research relating to yellow fever will be published shortly.
The discovery is highly significant for public health, as a chikungunya epidemic has been forecast for the coming two years in Brazil.
“Drug development is extremely costly and time-consuming. The process takes 12 years on average between the start of research and bringing the drug to market. The cost is on the order of US$1.5 billion or more,” Freitas-Junior said. “Sofosbuvir has been fully approved for human use. This means it can be readied for use against chikungunya in one to three years, for a much lower cost, estimated at approximately US$500,000.”
He noted that chikungunya is a severe disease not only owing to the acute episode itself – causing symptoms similar to those of dengue – but because it can cause complications that include highly debilitating joint pain lasting months or years. The patient may become incapacitated, unable to work and even bedridden.
“So far we have no vaccine, and our diagnostic tools need to be optimized,” he continued. “Sofosbuvir is something concrete that could become a powerful weapon against this virus. The results of our research could enable any interested institutions to begin clinical trials.”
Bonotto said, “We don’t yet know exactly how the drug works in molecular terms. What we discovered was the macroscopic result: elimination of the virus and preservation of cells. The drug has proven effective in treating hepatitis C because it inhibits the protein that synthesizes the viral genome. The same may happen in the case of chikungunya, but the action mechanism must be elucidated.”
Learn more: Hepatitis C drug rids organism of chikungunya and yellow fever viruses
The Latest on: Sofosbuvir
[google_news title=”” keyword=”sofosbuvir” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Sofosbuvir
- Cost-Effectiveness of Sofosbuvir-Based Treatments for Chronic Hepatitis C in the USon April 21, 2024 at 5:00 pm
As sofosbuvir also works for relapsers and non-responders with genotypes 2 and 3, we design a follow-up treatment of sofosbuvir plus ribavirin for patients who experience prior interferon ...
- Side Effects of Vosevi: What You Need to Knowon April 17, 2024 at 5:00 pm
Vosevi (sofosbuvir/velpatasvir/voxilaprevir) is a prescription drug used to treat chronic (long lasting) hepatitis C infection. Vosevi can cause side effects that ...
- Zepatier dosageon April 15, 2024 at 5:00 pm
Yes, the forms and how often you take each drug are similar. Zepatier and ledipasvir/sofosbuvir (Harvoni) are both oral tablets taken once per day to treat certain types of hepatitis C.
- How Does Sofosbuvir Work?on April 15, 2024 at 2:28 pm
C target=_blank>hepatitis C virus in the body. It is used in combination with other medications to treat chronic hepatitis C virus infection.This article provides an overview of the antiviral ...
- Vosevi dosageon April 3, 2024 at 5:00 pm
Vosevi (sofosbuvir/velpatasvir/voxilaprevir) is a brand-name drug prescribed for chronic hepatitis C in adults in certain situations. Vosevi comes as an oral tablet ...
- Cost-Effectiveness of Sofosbuvir-Based Treatments for Chronic Hepatitis C in the USon March 27, 2024 at 5:01 pm
However, if compared to Viekira + Pak, Harvoni, olysio + sovaldi and sofosbuvir + peginterferon + ribavirin are no longer efficient characterized with higher costs and lower QALYs. Thus ...
- Mutating hepatitis viruses make drug treatment difficult: Study highlights importance of variant profilingon January 23, 2024 at 9:37 am
The study team monitored two patients with chronic hepatitis E who had not previously responded to ribavirin and who were then treated with a combination of sofosbuvir and ribavirin. "In both ...
- Famotidine Injectionon October 15, 2021 at 6:46 am
May alter absorption of pH-dependent drugs (eg, atazanavir, erlotinib, ketoconazole, itraconazole, ledipasvir/sofosbuvir, nilotinib, rilpivirine). May potentiate CYP1A2 substrates (eg, tizanidine ...
- Famotidine Injection Preservative-freeon October 15, 2021 at 6:46 am
May alter absorption of pH-dependent drugs (eg, atazanavir, erlotinib, ketoconazole, itraconazole, ledipasvir/sofosbuvir, nilotinib, rilpivirine). May potentiate CYP1A2 substrates (eg, tizanidine ...
- Treatment for hepatitis Con July 19, 2014 at 2:08 pm
All approved DAAs are effective against hepatitis C genotype 1 and most are also active against genotype 4. Sofosbuvir/velpatasvir or sofosbuvir plus daclatasvir are recommended for genotypes 2 or 3.
via Bing News